Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Keros Therapeutics (KROS) Depreciation and Depletion (2019 - 2025)

Historic Depreciation and Depletion for Keros Therapeutics (KROS) over the last 7 years, with Q3 2025 value amounting to $395000.0.

  • Keros Therapeutics' Depreciation and Depletion rose 2579.62% to $395000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 million, marking a year-over-year increase of 2596.15%. This contributed to the annual value of $1.2 million for FY2024, which is 5079.75% up from last year.
  • According to the latest figures from Q3 2025, Keros Therapeutics' Depreciation and Depletion is $395000.0, which was up 2579.62% from $370000.0 recorded in Q2 2025.
  • In the past 5 years, Keros Therapeutics' Depreciation and Depletion ranged from a high of $395000.0 in Q3 2025 and a low of $80000.0 during Q1 2021
  • In the last 5 years, Keros Therapeutics' Depreciation and Depletion had a median value of $210000.0 in 2023 and averaged $221315.8.
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first surged by 23846.15% in 2022, then tumbled by 3798.7% in 2023.
  • Quarter analysis of 5 years shows Keros Therapeutics' Depreciation and Depletion stood at $104000.0 in 2021, then increased by 22.12% to $127000.0 in 2022, then surged by 94.49% to $247000.0 in 2023, then surged by 34.41% to $332000.0 in 2024, then increased by 18.98% to $395000.0 in 2025.
  • Its last three reported values are $395000.0 in Q3 2025, $370000.0 for Q2 2025, and $344000.0 during Q1 2025.